Quote:

---

The 13D group's plan is to nominate highly qualified Director Nominees, who once elected, will determine the best path forward to achieving Leronlimab's approval.

---

Do they or a new CEO they are sure to nominate know everything happening with the company? How long will it take them to get up to speed January of next year, later than that?

What they determine is the best path forward is not necessarily the best path forward for shareholders. You say it's for approval but you have no proof of that. Current management also has plans of approval earliest being COVID-19, longhaulers and HIV.

Since you do not know what their plans involve it could be a lowball buyout with golden parachutes, it could be stripping out leronlimab and leaving a shell company either could be the best path forward for them but not shareholders.